Skip to content
OpenCapital
Get started

ANI Pharmaceuticals ANIP EV / EBITDA

EV / EBITDA at other companies

Viatris logo
ViatrisVTRS
9.6×—
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
32.6×—
ALN
Alnylam PharmaceuticalsALNY
52.6×—
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
14×-8.7×
Amgen logo
AmgenAMGN
15.9×-1.3×
Organon logo
OrganonOGN
8×-1.0×

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.89B+18.3%
Enterprise value$1.88B+5.8%
P/E20.5×—
P/S2×-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%—
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Calculated from ANI Pharmaceuticals’s reported figures.

enterprise value/ebitda=8.1×

Based on the most recent quarter.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's EV / EBITDA?
ANI Pharmaceuticals (ANIP) reported EV / EBITDA of 8.1× in Q1 2026.
How has ANI Pharmaceuticals's EV / EBITDA changed year-over-year?
ANI Pharmaceuticals's EV / EBITDA decreased by 66.8% year-over-year, from 24.2× to 8.1×.
What is the long-term trend for ANI Pharmaceuticals's EV / EBITDA?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's EV / EBITDA has grown at a -17.3% compound annual growth rate (CAGR), from 23.1× to 8.9×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.